





33rd Annual Scientific Congress of **Malaysian Oncological Society 2022**

4th - 6th November 2022



Hillton & Le Méridien Kuala Lumpur, Malaysia



for Our Future In Cancer Care



MESSAGE FROM ORGANISING CHAIRPERSON

A warm hello to everyone.

It gives me great pleasure to welcome you to the **33rd Annual Scientific Congress of Malaysian Oncological Society 2022 (33rd ASCOMOS)**, which will be held from 4th to 6th November 2022 at Hilton & Le Meridien Kuala Lumpur, Malaysia. We look forward to meeting all of you face to face.

Within the past two years while everyone's attention was focused on the pandemic; we know that our brave patients, their families and doctors courageously continued their fight against cancer. It is in recognition of this valiant spirit that we chose the theme **RECONNECTING**, for our future in cancer care.

Our committee has worked hard to deliver an excellent 3 day educational programme that suits everyone's interests, be it fellow oncologists, medical officers and our much valued nurses and allied health professionals.

We have an array of prominent international and national speakers to deliver up to date lectures and involve you in engaging discussions throughout the congress. The gathering of great minds coupled with sharing of knowledge and new ideas underlies the key theme for our meeting this year.

We strongly encourage you to send your research work for our abstract section. All accepted abstracts will be awarded free registration and you will have the great opportunity to present your work at this congress.

We look forward to welcoming everyone in November, reconnecting with each other face to face and fostering the spirit of fellowship. Until then, stay safe and do visit our website https://ascomos.com/home for the latest updates on the conference.

Yours sincerely, **DR MALWINDER SINGH SANDHU**Organising Chairperson

ORGANISING COMMITTEE

Organising Chairperson Malwinder Singh Sandhu

Scientific Committee Adlinda Alip

Ainun Zubaidah Mohamed

David Lee Dai Wee Khairiyah Sidek

Marfu'ah Nik Eezamuddeen Mohd Khairul bin Mohd Zambri

Mohammad Shukri Jahit

Nisha Shariff Ooi Gim Chee Rozita Abdul Malik

Rangasamy Ramachandran

Sandya Subramaniam

Tan Chih Kiang

Wan Zamaniah Wan Ishak

Conference Dinner Norhidayu Bt Salimin
SBRT Workshop Sandya Subramaniam

Technical Committee Elaine Thong



4th November 2022

TIME		TRACK 1	TRACK 2	TRACK 3	
8.00 9.30		Registration			
		Miscellaneous	Head & Neck	SBRT Workshop	
9.30	9.50	Updates on NET - Oncology perspective	Artificial intelligence in head and neck cancers: Is this the future?		
9.50	10.10	Nuclear Medicine approach in NET management; present and the future	HPV positive oropharynx cancers: What is the best approach?	SBRT lung workshop	
10.10	10.20	Q&A	Q&A	Q&A	
10.20	10.55		Opening Ceremony		
10.55	11.05	Tea Break Tea Break		Tea Break	
11.05	11.25	Cancer of Unknown Primary - challenges and treatment strategies	Radiotherapy post- reconstructive surgery of head and neck cancer		
11.25	11.45	Management of GIST - Past, present and future	Managing toxicities from advanced radiotherapy techniques in head and neck cancer		
11.45	12.05	Ewing Sarcoma - First line therapy and beyond	Reirradiation in HnN cancer - How safe is safe?	SBRT lung workshop	
12.05	12.25	12.25 Melanoma: New insights and new therapies Role of EBV testing and adjuvant treatment in NPC			
12.25	12.45	Requirements for optimal surgery in sarcoma	Updates on systemic therapy of relapsed/ metastatic SCCHN		
12.45	13.00	Q&A	Q&A	Q&A	
1.00	2.00	Lunch symposium 1A	Lunch symposium 1B	Lunch symposium 1C	

continue next page



4th November 2022

TIME		TRACK 1	TRACK 2	TRACK 3
		Miscellaneous	Central Nervous System	SBRT Workshop
2.00	2.20	The impact of age in paediatric radiotherapy, is less more?		SBRT spine workshop
2.20	2.40	CT-based contouring in IGBT for cervical cancer	Case-based discussion: Low and high grade	
		Urology	glioma	
2.40	3.00	Sexual health in prostate cancer		
3.00	3.10	Q&A	Q&A	Q&A
3.10	3.55	Tea Symposium 1A	Tea Symposium 1B	Tea Symposium 1C
3.55	4.15	RARP vs SBRT for	Case-based discussion:	CDDT : I I
4.15	4.35	prostate cancer: A face-off	Multiple brain metastases	SBRT spine workshop
4.35	4.45	Q&A	Q&A	Q&A
7.00	10.00	Conference Dinner (by invitation only)		only)

DISCLAIMER: Whilst every attempt would be made to ensure all aspects of the conference mentioned in the Programme will take place as scheduled, the Organising Committee assumes no responsibility should it fail to materialize due to any unforeseen circumstances.



5th November 2022

TIME		TRACK 1	TRACK 2	TRACK 3	
8.30 9.00		Registration			
		Lung	Breast	Research	
9.00	9.20	Optimal biomarker testing in lung cancer	Understanding high recurrence risk in early breast cancer	Establishment of Asian Cancer Trial Network: ATLAS by Nakamura Kenichi	
9.20	9.40	Perioperative therapy in NSCLC	Chemotherapy in early breast cancer. What has changed?	Surrey Group	
9.40	10.00	Adjuvant therapy post radical treatment in stage 1 NSCLC	Immunotherapy in early breast cancer	Sarawak ASCO Centre	
10.00	00 10.15 Q&A Q&A		Q&A		
				Allied Health	
10.15	11.00	Breakfast Symposium 2A	Breakfast Symposium 2B	Breakfast Symposium 2C	
11.00	11.20	Treatment paradigm in resectable EGFR mutation positive NSCLC	Optimising adjuvant therapy for HER2 breast cancer	Role of nurses in oncology emergencies	
11.20	11.40		Adjuvant CDK4/6 inhibitor in HR+ HER2- early breast cancer	Care of intravenous therapy in oncology	
11.40	12.00	Locally advanced lung cancer: A multidisciplinary team approach	Making sense of PARP inhibition in early breast cancer	Nursing challenges in cancer patients	
12.00	12.20		Low ER positive breast cancer. The dilemma	Spiritual needs of cancer patients: Challenges among nurses	
12.20	12.40	Treatment approach in uncommon EGFRm+ in NSCLC	HR+ HER2- metastatic breast cancer: Beyond CDK4/6 inhibitors	Specialized home care nursing. Are you ready?	
12.40	1.00	Q&A	Q&A	Q&A	

continue next page



5th November 2022

TII	TIME TRA		TRACK 2	TRACK 3
1.00	2.00	Lunch Symposium 2A	ch Symposium 2A Lunch Symposium 2B	
2.00	2.20	Addressing resistance to immune checkpoint inhibitors	Case-based discussion:	EBRT dose calculation algorithm: The past, present and future
2.20	2.40	Uncommon mutations in NSCLC	Challenge your experts 1. ER Positive 2. HER2 Positive	
2.40	3.00	Maximising therapy for non-oncogene addicted NSCLC	3. TNBC	Physicists' perspective: Setting up an SBRT programme
3.00	3.10	Q&A	Q&A	Q&A
3.10	3.55	Tea Symposium 2A	Tea Symposium 2B	Tea Symposium 2C
3.55	4.15	Neoadjuvant treatment in SCLC	Beyond immunotherapy in metastatic TNBC	XVI dual registration tool for image-guided radiotherapy
4.15	4.35	Current treatment paradigm in Mesothelioma	Recent advances in HER2 positive advanced breast cancer	4DCT challenges: From the lens of a radiation therapist
4.35	4.45	Q&A	Q&A	Q&A
5.00	7.00	Annual General Meeting (MOS members only)		

DISCLAIMER: Whilst every attempt would be made to ensure all aspects of the conference mentioned in the Programme will take place as scheduled, the Organising Committee assumes no responsibility should it fail to materialize due to any unforeseen circumstances.



6th November 2022

TIME		TRACK 1	TRACK 2	TRACK 3		
8.30 9.00		Registration				
		Gastro Intestinal	Brachytherapy	Nutrition		
9.00	9.20	HCC - Novel agents beyond 1st line therapy	Brachytherapy for tongue carcinoma	Nutrition therapy team in cancer treatment: Reality or fiction?		
9.20	9.40	New updates in biliary tract malignancies				
9.40	10.00	Locally advanced pancreatic cancer: To palliate or to cure?	Brachytherapy vs SBRT liver	Enhancing nutritional support in difficult enteral access		
10.00	10.15	Q&A Q&A		Q&A		
10.15 11.00 Breakfast Symposium 3A		Breakfast Symposium 3A	Breakfast Symposium 3B	Breakfast Symposium 3C		
			Gynaecology			
11.00	11.20	Surgery in localised gastric and GOJ cancer	Cervical cancer screening in Malaysia: Removing Obstacles to Cervical Screening (ROSE)	A case of inadequate calories or protein? Why aren't they responding to therapy?		
11.20	11.40	Current therapy standard for early stage gastric & Impact on clir practice		Refeeding syndrome: The silent killer		
11.40	12.00	Immunotherapy in gastric and GOJ cancer - A long way to go?	Review of adjuvant treatment in endometrial cancer	Immunonutrition: The new silver bullet?		
12.00	12.20	Metastatic HER2+ gastric cancer - recent updates	Advances in immunotherapy for cervical cancer	Improving gut tolerance during chemotherapy		

continue next page



6th November 2022

TII	ME	TRACK 1	TRACK 2	TRACK 3
12.20	12.40	Immunotherapy in advanced oesophageal cancer	Platinum resistant ovarian cancer: Therapy updates	The role of microbiota during cancer therapy: friend or foe?
12.40	1.00	Q&A	Q&A	Q&A
1.00	2.00	Lunch Symposium 3A	Lunch Symposium 3B	Lunch Symposium 3C
				Fertility
2.00	2.20	New updates in advanced pancreatic cancer		Fertility boost for male cancer patients
2.20	2.40	Total neoadjuvant treatment in rectal cancer - Reality or myth?	Free paper presentation	Improving chance for pregnancy in female cancer patients
2.40	3.00	Avoidance of surgery after a pCR in rectal cancer		Unknown risks of new anti-cancer agents in pregnancy
3.00	3.15	Q&A	Q&A	Q&A
3.15	3.15 3.45 Closing Ceremony			

DISCLAIMER: Whilst every attempt would be made to ensure all aspects of the conference mentioned in the Programme will take place as scheduled, the Organising Committee assumes no responsibility should it fail to materialize due to any unforeseen circumstances.



ABSTRACT SUBMISSION

Important Dates

Call for abstracts submission: 15th May 2022
Abstract submission deadline: 1st August 2022
Abstract acceptance notification: 15th September 2022

Abstract Guideline

- 1. The abstract must be limited to 300 words.
- 2. Font size: 12.
- 3. Font Type: Times New Roman.
- 4. No table or illustrations allowed.
- 5. Spacing and Alignment: Single spacing and justified fields.
- 6. If the abstract contains identifiers e.g. name of hospital in the text body, the authors need to underline them in order for the secretariat to omit them when it is sent for evaluation.

Format of Content to Follow Research/Study Format - Introduction

- Materials and Methods
- Results
- Discussion (s)
- Conclusion (s)
- Reference (s)

Case Study Format - Introduction

- Report
- Conclusion (s)
- Reference (s)

Rules

- Corresponding author / presenter must register for the Congress before submission of abstract.
- It is recommended that the corresponding authors / presenters wait for the notification of acceptance before making payment for the Congress.
- 3. One author / presenter may submit more than one abstract.
- 4. Accepted abstract will be communicated through email on 15th September 2022.
- 5. Oral presentation abstracts will be shortlisted by the Scientific Committee. Preference of the author will not be considered.

Remark: Free conference registration is provided for all accepted abstract.

REGISTRATION FEES

Fee Category	Early Bird Rate 30th June 2022	Regular Rate 1st July 2022 - 28th October 2022	On Site Rate
MOS Member	MYR 1,000	MYR 1,500	MYR 2,000
Non MOS Member	MYR 1,500	MYR 2,000	MYR 2,500
Allied Health/Student/Trainee	MYR 750	MYR 1,000	MYR 1,250
International	USD 750	USD 1,000	USD 1,250
Submit Abstract	FOC	FOC	N/A
Virtual Access 7th November - 6 December 2022		MYR 200	

- Your registration covers 3 days of conference with meals, entry of all sub-session, workshop (limited space base on first come first serve basic) and conference collaterals.
- An e-certificate of attendance will be issued to all registered delegates after the conference.



PAYMENT METHODS

Offline Payment	Online Payment
Payment methods are: Online Transfer Cash Cheque Please make payment before registering online as you are required to attach the proof of payment (scanned document of deposit slip / payment proof) in the online registration page.	Payment can be made during online registration. Payment methods are: JomPay Biller Code: 96716 Biller Code Name: The M'sian Oncological Society Steps: Log in to your preferred Internet or Mobile Banking. Select JomPay payment method. Key in the following: i. Biller Code: 96716 ii. Ref-1: Registration ID that you receive in the acknowledgement email iii. Ref-2: 33rd ASCOMOS iv. Payment Amount: as stated in the acknowledgement chit in Ringgit Malaysia Complete your payment.

Please note that all related bank charges and/or financial charges are to be borne by the delegates and are not to be deducted from the nett fee payable to the conference. Official receipt will be provided only upon request.

All payments are to be issued in favour of:

Account Name: THE MALAYSIAN ONCOLOGICAL SOCIETY

Bank Name: RHB Bank Berhad
Bank Account No: 2143-8900-0653-69

SWIFT Code: RHBBMYKL

Bank Address: 15 & 17 Jalan Tun Mohd Fuad 3, Taman Tun Dr Ismail, 60000 WP Kuala Lumpur

Cancellation and Refund Policy

The Secretariat must be notified in writing of all cancellations. Refund will be made only after the conference and only applicable under the following circumstances:

Cancellation before 30 September 2022 : **50% refund** Cancellation after 30 September 2022 : **No refund**

If no refund is required but a change in participant registration is needed, then the Secretariat must be informed in writing via email to secretariat@ascomosmos.com

Liability

The Organising Committee will not be liable for personal accidents, loss or damage to private property of the participants during duration of the Conference. Participants should make their own personal arrangements.

Disclaimer

Whilst every attempt is made to ensure that all aspect of the conference as mentioned in this announcement will take place as scheduled, the Organising Committee reserves the right to make last minute changes should the need arise.



Contact Us

33rd ASCOMOS Secretariat c/o Medical Conference Partners 9, Jalan 9/3, Section 9, 46000, Petaling Jaya, Selangor, Malaysia

Tel: +603 7931 2856 **Email:** secretariat@ascomos.com

Malaysian Oncological Society website: www.malaysiaoncology.org





Registration and exhibition: secretariat@ascomos.com Speaker and Programme: speaker@ascomos.com

Abstract: abstract@ascomos.com

